MX2022010093A - Tafoxiparina para el tratamiento de la preeclampsia. - Google Patents

Tafoxiparina para el tratamiento de la preeclampsia.

Info

Publication number
MX2022010093A
MX2022010093A MX2022010093A MX2022010093A MX2022010093A MX 2022010093 A MX2022010093 A MX 2022010093A MX 2022010093 A MX2022010093 A MX 2022010093A MX 2022010093 A MX2022010093 A MX 2022010093A MX 2022010093 A MX2022010093 A MX 2022010093A
Authority
MX
Mexico
Prior art keywords
tafoxiparin
preeclampsia
treatment
combination
therapy
Prior art date
Application number
MX2022010093A
Other languages
English (en)
Inventor
Gunvor Ekman-Ordeberg
Stefan Hansson
Lena Degling-Wikingsson
Original Assignee
Dilafor Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dilafor Ab filed Critical Dilafor Ab
Publication of MX2022010093A publication Critical patent/MX2022010093A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invención se relaciona con el uso de la tafoxiparina derivada de heparina en el tratamiento de la preeclampsia (PE). El tratamiento puede ser monoterapia o terapia de combinación, donde la tafoxiparina se utiliza en combinación con un agente (fármaco) utilizado como terapia para cuidado estándar de la preeclampsia (PE).
MX2022010093A 2020-02-17 2021-02-16 Tafoxiparina para el tratamiento de la preeclampsia. MX2022010093A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE2000033 2020-02-17
PCT/EP2021/053733 WO2021165240A1 (en) 2020-02-17 2021-02-16 Tafoxiparin for the treatment of preeclampsia

Publications (1)

Publication Number Publication Date
MX2022010093A true MX2022010093A (es) 2022-09-02

Family

ID=74668828

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010093A MX2022010093A (es) 2020-02-17 2021-02-16 Tafoxiparina para el tratamiento de la preeclampsia.

Country Status (13)

Country Link
US (1) US20230144378A1 (es)
EP (1) EP4106765A1 (es)
JP (1) JP2023512920A (es)
KR (1) KR20220142508A (es)
CN (1) CN115103679A (es)
AU (1) AU2021223494A1 (es)
BR (1) BR112022014456A2 (es)
CA (1) CA3169421A1 (es)
CL (1) CL2022002239A1 (es)
CO (1) CO2022013055A2 (es)
IL (1) IL295184A (es)
MX (1) MX2022010093A (es)
WO (1) WO2021165240A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4272749A1 (en) 2022-05-03 2023-11-08 Dilafor AB New medical use of tafoxiparin
TW202406559A (zh) 2022-05-03 2024-02-16 瑞典商迪拉佛公司 塔夫西肝素(tafoxiparin)之新穎醫藥用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127896A0 (en) * 1998-12-31 1999-10-28 Gail Laster A novel treatment for preeclampsia and related diseases
SE521676C2 (sv) 2002-01-02 2003-11-25 Dilafor Ab Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
US20070292421A1 (en) * 2005-07-28 2007-12-20 Feinberg Bruce B Method for treating preeclampsia
ME02994B (me) 2011-12-19 2018-10-20 Dilafor Ab Glikozaminoglikani koji nisu anтikoagulanтi koji sadrže ponavljajuću jedinicu disaharida i njihova medicinska upotreba
UA117908C2 (uk) 2012-03-26 2018-10-25 Ділафор Аб Застосування гепарину або гепарансульфату для індукції пологів
MY185108A (en) 2012-03-26 2021-04-30 Dilafor Ab Method for treatment of labor arrest
CA2868403A1 (en) 2012-05-08 2013-11-14 Dilafor Ab Treatment of postpartum haemorrhage with chemically modified heparin or heparan sulphate and a uterotonic agent
GB2515315A (en) 2013-06-19 2014-12-24 Dilafor Ab New Processes

Also Published As

Publication number Publication date
US20230144378A1 (en) 2023-05-11
CA3169421A1 (en) 2021-08-26
CL2022002239A1 (es) 2023-04-10
KR20220142508A (ko) 2022-10-21
BR112022014456A2 (pt) 2022-09-13
CO2022013055A2 (es) 2022-09-30
JP2023512920A (ja) 2023-03-30
CN115103679A (zh) 2022-09-23
IL295184A (en) 2022-09-01
EP4106765A1 (en) 2022-12-28
AU2021223494A1 (en) 2022-08-04
WO2021165240A1 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
MX2022009164A (es) N4-hidroxicitidina y derivados y usos antivirales relacionados con los mismos.
MX2017015938A (es) Inhibidores de ezh2 para el tratar linfomas.
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
SG10201902429PA (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
MX2017013142A (es) Terapia combinada para tratar cáncer.
MX2016008013A (es) Conjugados de farmacos anticuerpo (adcs) con inhibidores de ksp.
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
MY182590A (en) Benzylamine derivatives
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
MX2021010173A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2022010093A (es) Tafoxiparina para el tratamiento de la preeclampsia.
BR112022001341A2 (pt) Inibidores de enzima
MX2021006156A (es) Compuestos utiles en la terapia para el vih.
MX2019013862A (es) Terapia de combinacion.
MX2020001727A (es) Terapia de combinacion.
GEP20247585B (en) Furoindazole derivatives
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
MX2021001612A (es) Compuestos utiles en terapia del vih.
WO2019043176A3 (en) HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY
NZ745187A (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
MX2022000811A (es) Inhibidores de enzimas.
MX2021000542A (es) Apirasas solubilizadas, metodos y usos.
AU2017258649A1 (en) Covalent BTK inhibitors and uses thereof